Balyasny Asset Management L.P. Makes New Investment in Oscar Health, Inc. (NYSE:OSCR)

Balyasny Asset Management L.P. acquired a new position in shares of Oscar Health, Inc. (NYSE:OSCR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 148,211 shares of the company's stock, valued at approximately $1,992,000. Balyasny Asset Management L.P. owned about 0.06% of Oscar Health as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of OSCR. BNP Paribas Financial Markets acquired a new position in shares of Oscar Health during the 4th quarter worth $590,000. Ameriprise Financial Inc. grew its stake in shares of Oscar Health by 3,062.3% during the 4th quarter. Ameriprise Financial Inc. now owns 976,563 shares of the company's stock worth $13,125,000 after purchasing an additional 945,682 shares during the period. Ancient Art L.P. grew its stake in shares of Oscar Health by 66.8% during the 4th quarter. Ancient Art L.P. now owns 2,950,753 shares of the company's stock worth $39,658,000 after purchasing an additional 1,182,134 shares during the period. Ardsley Advisory Partners LP grew its stake in shares of Oscar Health by 2.0% during the 4th quarter. Ardsley Advisory Partners LP now owns 1,125,000 shares of the company's stock worth $15,120,000 after purchasing an additional 22,400 shares during the period. Finally, Comerica Bank grew its stake in shares of Oscar Health by 41.3% during the 4th quarter. Comerica Bank now owns 128,810 shares of the company's stock worth $1,731,000 after purchasing an additional 37,675 shares during the period. Hedge funds and other institutional investors own 75.70% of the company's stock.

Analyst Ratings Changes

Separately, Wells Fargo & Company cut shares of Oscar Health from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $20.00 to $16.00 in a research note on Thursday, March 13th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Oscar Health currently has an average rating of "Hold" and a consensus target price of $20.08.

Oscar Health Price Performance

Shares of NYSE OSCR opened at $16.76 on Tuesday. The stock has a market cap of $4.20 billion, a price-to-earnings ratio of -837.38 and a beta of 1.75. Oscar Health, Inc. has a 52 week low of $11.20 and a 52 week high of $23.79. The company's 50-day moving average price is $13.35 and its 200 day moving average price is $14.62. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $0.09. Oscar Health had a net margin of 0.28% and a return on equity of 2.28%. The firm had revenue of $3 billion for the quarter, compared to analysts' expectations of $2.87 billion. During the same period in the prior year, the company earned $0.62 EPS. The firm's revenue was up 42.2% on a year-over-year basis. As a group, research analysts forecast that Oscar Health, Inc. will post 0.69 earnings per share for the current fiscal year.

Oscar Health Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.